
    
      A Phase I/Randomized Phase II clinical trial of pembrolizumab and vorinostat in Eastern
      Cooperative Oncology Group (ECOG) 0-1 patients with immune therapy na√Øve and immune therapy
      pretreated locally advanced or metastatic NSCLC who have progressed through one prior line of
      therapy.

      The begins with a phase I dose escalation utilizing the modified continuous reassessment
      method (O'Quigley, Pepe, & Fisher, 1990). This would be followed by a phase I expansion at
      the maximum tolerated dose (MTD) in 18 NSCLC patients who have been previously treated with
      anti-PD-1 or anti-PD-L1 therapy. In parallel, a separate phase II arm will randomize 70
      patients to a pembrolizumab alone group and a pembrolizumab plus vorinostat group.
    
  